After the company announced top-line data from an important phase 3 trial, shares of Nabriva Therapeutics (NASDAQ: NBRV), a clinical-stage biotech focused on next-generation antibiotics, fell as much as 14% in morning trading on Monday. As of 11:20 a.m. EDT, the stock was down 9%.Nabriva announced top-line results from its Leap 2 study today.